GleamWall
中文EN

ADXN Addex Therapeutics Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1574232 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-74.9%
TTM net income YoY166.8%
TTM EPS YoY150.0%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-681.8%
Net margin1,746.0%
FCF margin-1,330.1%
EBITDA margin—

Returns

ROE130.4%
ROA92.1%
ROIC (approx.)-120.4%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets9.4%
Debt / equity0.00x
Current ratio4.42x
Interest coverage-1,712.39x

Cash quality & payout

Operating cash flow / net income-0.76x
Accruals ratio162.3%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF 2025Q2*2025-06-302025-03-31*2025-03-312024Q2*2024-06-302024Q1*2024-03-312023Q2*2023-06-302023Q1*2023-03-312022Q2*2022-06-302022Q1*2022-03-31
Income statement
Revenue——115,277—630,877—183,354—
R&D expense234,454—339,317—1.88M—5.75M—
SG&A expense534,819—675,276—1.30M—1.53M—
Operating income-732,898—-899,316—-2.55M—-7.09M—
Interest expense334—437—93—7,574—
Pretax income-1.96M—-1.46M—-2.68M—-7.22M—
Income tax————0—0—
Net income-1.84M-1.47M12.88M-3.09M-2.68M-2.41M-7.22M-5.82M
EPS (basic)-0.02—0.13—-0.04—-0.19—
EPS (diluted)-0.02—0.13—-0.04—-0.19—
Weighted avg. shares (diluted)100.52M—98.31M—————
Balance sheet
Cash & equivalents2.30M—3.79M—7.17M—8.81M—
Receivables38,439———255,656—331,770—
Current assets2.66M———8.69M—10.95M—
PP&E, netmay include right-of-use assets (IFRS)919———33,154—54,431—
Total assets8.51M———9.00M—11.38M—
Current liabilities1.15M———2.71M—4.30M—
Total liabilities1.29M———2.87M—4.52M—
Shareholders' equity7.21M8.30M12.65M-1.37M6.13M4.07M6.86M12.96M
Shares outstanding141.19M—128.25M—92.35M—37.88M—
Cash flow statement
Operating cash flow————————
Capital expenditure0—0—————
Stock-based compensation1,851—4,701—416,947—550,221—

Free plan shows the latest 8 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.